How Do I Get My Compound Into Phase I?

Presented by

Scott Boley, PhD, DABT, Greg Ruppert, BA

About this talk

Careful assessment of the relationship between efficacy and toxicity is vital to drug developers as they seek advancement of their compounds. Nonclinical testing is required to establish a safe starting dose for the initial human clinical trials. In partnering with our pharmaceutical and biotechnology Sponsors, our goal is to improve the odds of selecting the right lead candidates, and to conduct the right studies in the right way, taking all factors into consideration to ensure a successful IND submission. As part of this webinar we will outline the nonclinical studies needed to progress a therapeutic into a Phase I clinical trial. We will cover small molecules to vaccines to biopharmaceuticals as well as standard indications to life-threatening and rare/orphan indications.

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (18)
Subscribers (2020)
MPI Research exceeds expectations through consistency and quality, with a commitment to communication and innovation, delivering benefits throughout all phases of drug and device development. Learn how we can go beyond for you at www.mpiresearch.com.